• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Azitra Inc

    7/29/24 4:01:02 PM ET
    $AZTR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AZTR alert in real time by email
    SC 13G 1 l1cap_13g.htm SCHEDULE 13G

     

    SECURITIES AND EXCHANGE COMMISSION

     

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

     

    Azitra, Inc.
    (Name of Issuer)
     
    Common Stock, par value $0.0001 per share
    (Title of Class of Securities)
     
    05479L203
    (CUSIP Number)
     
    July 24, 2024
    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☐ Rule 13d-1(b)

     

    ☒ Rule 13d-1(c)

     

    ☐ Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities and Exchange Act of 1934 (the “Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     
     

     

     

    CUSIP No.  05479L203   13G   Page 2 of 5 Pages

     

    1  NAME OF REPORTING PERSONS
       
      L1 Capital Global Opportunities Master Fund, Ltd.
    2 CHECK THE APPROPRIATE BOX IF MEMBER OF A GROUP
     

     

    (a)  ☐

      (b)  ☐
    3 SEC USE ONLY
       
       
    4 CITIZENSHIP OR PLACE OF ORGANIZATION
       
      Cayman Islands 
      5                  SOLE VOTING POWER
         
         776,375(1)(2)
    NUMBER OF 6 SHARED VOTING POWER
    SHARES    
    BENEFICIALLY    0
    OWNED BY 7 SOLE DISPOSITIVE POWER
    EACH REPORTING    
    PERSON WITH   776,375(1)(2)
      8 SHARED DISPOSITIVE POWER
         
        0
    9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
       
       776,375(1)(2)
    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     

     

    ☐

    11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
       
       9.99% (1)(2)
    12 TYPE OF REPORTING PERSON
     

     

    FI (3)

           

     

    (1)Represents 630,000 shares of the Issuer’s Common Stock held by the Reporting Person and 146,375 shares of Common Stock issuable upon the exercise of Class A Warrants held by the Reporting Person which are exercisable within 60 days, subject to a 9.99% beneficial ownership limitation. Does not include 483,625 shares of Common Stock underlying Class A Warrants held by the Reporting Person which are subject to the 9.99% beneficial ownership limitation.

    (2)Based on 7,625,146 shares of Common Stock outstanding upon the closing of an offering as reported in the Issuer’s Prospectus dated July 23, 2024.

    (3)The Reporting Person has not acquired the securities with any purpose, or with the effect, of changing or influencing the control of the Issuer, or in connection with or as a participant in any transaction having that purpose or effect, including any transaction subject to Rule 13d-3(b).

     

     
     

     

     

    CUSIP No.  05479L203   13G   Page 3 of 5 Pages

     

    Item 1.

     

      (a) Name of Issuer:

     

    Azitra, Inc.

     

     

    (b)

     

    Address of Issuer’s Principal Executive Offices:

     

    21 Business Park Drive, Suite 6

    Branford, CT 06405

     

    Item 2.

     

    (a)  Name of Person Filing:
       
      L1 Capital Global Opportunities Master Fund, Ltd.
       
    (b)   Address of Principal Business Office or, if none, Residence:
       
     

    161A Shedden Road, 1 Artillery Court

    PO Box 10085

    Grand Cayman, Cayman Islands KY1-1001

       
    (c) Citizenship:
       
      Cayman Islands
       
    (d) Title of Class of Securities:
       
      Common Stock, par value $0.0001 per share
       
    (e)  CUSIP Number:
       
      05479L203

     

    Item 3.

     

    Not applicable. 

     

     
     

     

     

     CUSIP No. 05479L203   13G   Page 4 of 5 Pages

     

    Item 4. Ownership.

     

    (a)–(c)   The information required by Items 4(a)-(c) is set forth in Rows (5)-(9) and Row (11) of the cover page and is incorporated herein by reference.

     

        The percentage set forth on Row (11) of the cover page for the reporting person is based on 7,625,146 shares of Common Stock outstanding upon the closing of an offering based on the Issuer’s Prospectus dated July 23, 2024.

     

        David Feldman and Joel Arber are the Directors of L1 Capital Global Opportunities Master Fund, Ltd. As such, L1 Capital Global Opportunities Master Fund, Ltd., Mr. Feldman, and Mr. Arber may be deemed to beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934) the issuer’s securities described herein. To the extent Mr. Feldman and Mr. Arber are deemed to beneficially own such securities, Mr. Feldman and Mr. Arber disclaim beneficial ownership of these securities for all other purposes.

     

    Item 5.

    Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☐

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable.

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

     

    Not applicable.

     

    Item 8. Identification and Classification of Members of the Group.

     

    Not applicable.

     

    Item 9. Notice of Dissolution of Group.

     

    Not applicable.

     

    Item 10.

    Certifications.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     
     

     

     

    CUSIP No.  05479L203   13G   Page 5 of 5 Pages

     

    SIGNATURES

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete, and correct.

     

       
      By:    L1 Capital Global Opportunities Master Fund, Ltd.
         
    July 29, 2024 By:  /s/ David Feldman
        David Feldman, Director

     

    Get the next $AZTR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AZTR

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $AZTR
    SEC Filings

    See more
    • SEC Form PRE 14A filed by Azitra Inc

      PRE 14A - Azitra, Inc. (0001701478) (Filer)

      5/19/25 4:30:39 PM ET
      $AZTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SCHEDULE 13G filed by Azitra Inc

      SCHEDULE 13G - Azitra, Inc. (0001701478) (Subject)

      5/14/25 2:52:17 PM ET
      $AZTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Azitra Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Azitra, Inc. (0001701478) (Filer)

      5/13/25 5:05:23 PM ET
      $AZTR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AZTR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $AZTR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Amendment: SEC Form SC 13G/A filed by Azitra Inc

      SC 13G/A - Azitra, Inc. (0001701478) (Subject)

      11/14/24 12:56:51 PM ET
      $AZTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Azitra Inc

      SC 13G/A - Azitra, Inc. (0001701478) (Subject)

      11/14/24 12:18:21 PM ET
      $AZTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Azitra Inc

      SC 13G/A - Azitra, Inc. (0001701478) (Subject)

      11/6/24 4:35:43 PM ET
      $AZTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Azitra, Inc. to Present Abstract at American Society of Gene and Cell Therapy Highlighting Phase 1/2 Study Targeting Cancer Therapy-Associated Rash

      Azitra plans to dose first patient in a Phase 1/2 trial in the first half of 2025 for its precision dermatology candidate ATR04-484, designed for the treatment of EGFR inhibitor-associated rash BRANFORD, Conn., May 14, 2025 /PRNewswire/ -- Azitra, Inc. (NYSE:AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that it will present a poster describing the Phase 1/2 clinical trial of ATR04-484 for EGFR inhibitor ("EGFRi")-associated rash at the 28th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT). ASGCT is being held May 13-17, 2025, in New Orleans, Louisiana.

      5/14/25 4:05:00 PM ET
      $AZTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Azitra, Inc. Announces Q1 2025 Results and Provides Business Updates

      BRANFORD, Conn., May 13, 2025 /PRNewswire/ -- Azitra, Inc. (NYSE:AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today reported financial results for the quarter ended March 31, 2025, and provided a business update. Q1 2025 and Recent Business Highlights Announced acceptance of poster detailing the Phase 1/2 clinical trial of the ATR-04 program in EGFR inhibitor ("EGFRi")-associated rash at the 2025 American Society of Clinical Oncology (ASCO) Annual MeetingEntered into Purchase Agreement for up to $20 Mil

      5/13/25 5:06:00 PM ET
      $AZTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Azitra, Inc. to Present ATR-04 Program Update at ASCO 2025

      Azitra is developing ATR04-484 for the treatment of EGFR inhibitor-associated rash with plans to dose first patient in Phase 1/2 trial in the first half of 2025 BRANFORD, Conn., April 25, 2025 /PRNewswire/ -- Azitra, Inc. (NYSE:AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that an abstract detailing the Phase 1/2 clinical trial of ATR04-484 in EGFR inhibitor ("EGFRi")-associated rash has been accepted for presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting being held May 30-June 3, 2025 in Chicago.

      4/25/25 8:33:00 AM ET
      $AZTR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AZTR
    Leadership Updates

    Live Leadership Updates

    See more
    • Azitra, Inc. Appoints Travis Whitfill as Chief Operating Officer

      BRANFORD, Conn., July 11, 2023 /PRNewswire/ -- Azitra, Inc. (NYSE:AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced the appointment of Travis Whitfill as Chief Operating Officer. Mr. Whitfill is the cofounder of Azitra and joins from Bios Partners, a venture capital firm focused on investing in early-stage biopharmaceutical companies. "We are delighted to welcome Travis back to Azitra full time, after his tenure of nearly ten years in biotech venture capital," said Francisco Salva, President and CEO of Azitra. "Travis brings a wealth of knowledge in biotech, synthetic biology, and drug development. He will

      7/11/23 4:05:00 PM ET
      $AZTR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AZTR
    Financials

    Live finance-specific insights

    See more
    • Azitra, Inc. Announces Full Year 2024 Financial Results and Provides Business Updates

      BRANFORD, Conn., Feb. 20, 2025 /PRNewswire/ -- Azitra, Inc. (NYSE:AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today reported financial results for the full year ended December 31, 2024, and provided a business update. FY 2024 and Recent Business Highlights Initiated a Phase 1b clinical trial investigating ATR-12 in adult Netherton syndrome patients; Initial safety data from first set of Netherton syndrome patients expected in the first half of 2025 with topline data from the Phase 1b trial by year-end 2025Received clearance from the U.S. Food and Drug Administration (FDA) for a first-in-human Phase 1/2 clinical stu

      2/24/25 8:30:00 AM ET
      $AZTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Azitra, Inc. Announces Q3 2024 Financial Results and Provides Business Updates

      BRANFORD, Conn., Nov. 12, 2024 /PRNewswire/ -- Azitra, Inc. (NYSE:AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today reported financial results for the three months ended September 30, 2024 and provided a business update. Q3 2024 and Recent Business Highlights: Completed a follow-on offering of $10 million in gross proceedsDosed first Netherton syndrome patient with ATR-12Submitted an IND to the FDA and received IND clearance for ATR-04 to treat skin rash from EGFR inhibitorsReceived Fast Track designat

      11/12/24 5:05:00 PM ET
      $AZTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Azitra, Inc. Announces Q2 2024 Financial Results and Provides Business Updates

      Azitra, Inc. (NYSE:AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today reported financial results for the three months ended June 30, 2024, and provided a business update. Q2 2024 and Recent Business Highlights Completed a follow-on offering of $10 million in gross proceeds expected to provide cash runway into 2025. With the recent financing, the company anticipates announcing multiple clinical milestones Strengthened global intellectual property portfolio with newly granted and allowed patents Exhibited positive preclinical data from ATR-04 at the Society of Investigative Dermatology Annual Meeting Pres

      8/12/24 6:23:00 PM ET
      $AZTR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AZTR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Staskey Norm bought $10,034 worth of shares (47,600 units at $0.21), increasing direct ownership by 1,360% to 51,100 units (SEC Form 4)

      4 - Azitra, Inc. (0001701478) (Issuer)

      4/1/24 9:51:59 PM ET
      $AZTR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AZTR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Staskey Norm bought $10,034 worth of shares (47,600 units at $0.21), increasing direct ownership by 1,360% to 51,100 units (SEC Form 4)

      4 - Azitra, Inc. (0001701478) (Issuer)

      4/1/24 9:51:59 PM ET
      $AZTR
      Biotechnology: Pharmaceutical Preparations
      Health Care